Takuto Kojima

This inventor holds 27 USPTO granted patents and 10 published patent applications, plus 4 CIPO patents and 8 EPO patents, primarily in Heterocyclic Compounds. Top assignee: Takeda Pharmaceutical Company Limited. Active years: 2014-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Takuto Kojima. Retrieved from https://idiyas.com/inventor/takuto-kojima

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 27 (Patent Applications = 10)

% Patents Active = 81.5

CIPO Patents = 4 (Patent Applications = 5)

EPO Patents = 8 (Patent Applications = 14)

Average Co-Inventor Count = 8.8

ph-index = 5

Forward Citations = 85(Granted Patents)

Location History:

Osaka, JP (2014)
Fujisawa, JP (2019 - 2022)
Kanagawa, JP (2016 - 2024)

Company Filing History:

27 out of 1,226

Takeda Pharmaceutical Company Limited

patents

Years Active: 2014-2024

Loading Chart...

Areas of Expertise:

Heterocyclic Compound

Fused Heterocyclic Compound

Cyclopropanamine

Cholinergic Modulator

HDAC6 Inhibitor

Quinazolinone

Benzotriazinone

Tricyclic Compounds

Pharmaceutical Compositions

Corticotropin-Releasing Factor

Nitrogen-Containing Compounds

Bicyclic Heterocyclic

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12084436 - Heterocyclic compound (2024-09-10),

2. 11390634 - Fused heterocyclic compound (2022-07-19),

3. 10981934 - Fused heterocyclic compound (2021-04-20),

4. 10968213 - Cyclopropanamine compound and use thereof (2021-04-06),

5. 10899752 - 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor (2021-01-26),

6. 10696651 - Heterocyclic compound (2020-06-30),

7. 10676461 - Heterocyclic compound (2020-06-09),

8. 10577382 - Fused heterocyclic compound (2020-03-03),

9. 10548899 - Quinazolinone and benzotriazinone compounds with cholinergic muscarinin M1 receptor positive allosteric modulator activity (2020-02-04),

10. 10519110 - Heterocyclic compound (2019-12-31),

11. 10435399 - HDAC6 inhibitory heterocyclic compound (2019-10-08),

12. 10428056 - Heterocyclic compound (2019-10-01),

13. 10414761 - Cyclopropanamine compound and use thereof (2019-09-17),

14. 10323027 - 2,3-dihydro-4H-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor (2019-06-18),

15. 10208046 - Nitrogen-containing heterocyclic compound (2019-02-19),

Title: The Innovations of Takuto Kojima: Pioneering Advances in Pharmaceutical Chemistry

Introduction: Takuto Kojima is a distinguished inventor based in Kanagawa, Japan. With a remarkable portfolio comprising 27 patents, he has made significant contributions to the field of pharmaceutical chemistry. Kojima's innovative work focuses on the development of compounds that possess therapeutic benefits, particularly in the treatment of central nervous system diseases.

Latest Patents: Two of Takuto Kojima's latest patents highlight his expertise in heterocyclic compounds. One notable patent describes a heterocyclic compound with HDAC inhibitory action, aimed at treating neurodegenerative diseases and similar conditions. The invention provides a compound represented by a specific formula, or a salt thereof, making it a valuable asset in medical research. Additionally, he has developed a fused heterocyclic compound, represented by another unique formula, further expanding the possibilities for medical applications.

Career Highlights: Takuto Kojima is currently employed at Takeda Pharmaceutical Company Limited, a leading global biopharmaceutical company. His work at Takeda has allowed him to focus on innovative drug discovery, with a particular emphasis on compounds that can impact patient health positively. His dedication to advancing medical treatments through innovative chemistry is evident in his extensive patent portfolio.

Collaborations: Throughout his career, Kojima has collaborated with notable colleagues, including Yasushi Hattori and Masashi Toyofuku. Their combined expertise fosters an environment of innovation and encourages the development of groundbreaking solutions in the pharmaceutical industry.

Conclusion: Takuto Kojima's contributions to the field of pharmaceutical chemistry and his commitment to improving treatment options through innovative compounds make him a respected figure in the realm of invention. His work demonstrates the impact of dedicated research and collaboration among inventors, paving the way for future advancements in medicine.

Profile summary based on public USPTO records.